We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Johnson & Johnson to Acquire Tibotec-Virco

By Biotechdaily staff writers
Posted on 22 May 2002
In a move that will expand its capabilities in drug-development, Johnson & Johnson (New Brunswick, NJ, USA) has agreed to acquire Tibotec-Virco NV (Mechelen, Belgium). More...
The transaction is valued at about US$320 million in cash and debt.

Tibotec-Virco is focused on developing antiviral treatments and has several promising compounds in development for the treatment of infectious diseases, including drug-resistant HIV and hepatitis C. The company provides HIV drug resistance testing and other analytical services under the name of Virco. Tibotec also has operations in Ireland and the United States.

"Tibotec-Virco will provide a good strategic fit with our current pharmacuetical research and development operations,” said Dr. Per Peterson, chairman, research & development for the pharmaceuticals group of J&J. "By combining Tibotec-Virco's expertise with our own research and development activities, we will expand our drug discovery and development capabilities, particularly in the field of antiviral therapies.”




Related Links:
Johnson & Johnson
Tibotec

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.